The purpose of the present study was to correlate gyrA mutations found in Mycobacterium tuberculosis isolates using the GenoType® MTBDRsl assay with minimum inhibitory concentrations of the fluoroquinolone levofloxacin (LVX). Of 123 archived clinical M. tuberculosis isolates evaluated, 93 isolates had an Ala90Val, Ser91Pro, Asp94Ala, Asn/Tyr, Gly or His mutation and 30 were wild-type. Phenotypically, gyrA mutations Ala90Val, Ser91Pro or Asp94Ala showed a low level of resistance to LVX, while Asp94Asn/Tyr, Asp94Gly or Asp94His mutations had high-level resistance.
Kambli, P.; Ajbani, K.; Nikam, C.; Khillari, A.; Shetty, A.; Udwadia, Z.; Georghiou, S.B.; Rodwell, T.C.; Catanzaro, A.; Rodrigues, C. Determination of MICs of levofloxacin for IMycobacterium tuberculosisI with IgyrIA mutations. International Journal of Tuberculosis and Lung Disease (2015) 19 (10) 1227-1229. [DOI: 10.5588/ijtld.14.0277]